1Assistant Professor, Department of Biology, Faculty of Sciences, AzarbaijanShahidMadani University, Tabriz, Iran
2Master of Genetics, Department of Animal Biology, Faculty of Natural Sciences, Tabriz University, Tabriz, Iran
3Professor of Radiobiology, Department of Animal Biology, Faculty of Natural Sciences, Tabriz University, Tabriz, Iran
Background: Due to the lack of information about the role of 4G/5G polymorphism of PAI-1 Gene in susceptibility to thyroid tumors, this study was performed to evaluate the potential effects of this polymorphism on clinicopathologic features of thyroid tumors in Iranian Azeri Turkish patients. Methods:In this case-control study, 90 patients with thyroid tumors who were not blood relatives and their PAI-1 4G/5G polymorphism had been determined in the previous study, were included. Results: All clinicopathologic features of thyroid tumor related to PAI-1 4G/5G polymorphism that affect the severity of disease were studied. The results show that T1 tumor size (4G/4G, P = 0.019; 4G/5G, P = 0.021) in patients with/without these features was significantly different. Conclusion: Data showed a protective role for 4G allele versus 5G and 4G/4G versus 5G/5G against the development of thyroid tumors in Azeri Turkish ethnic group.
Khayamzadeh M, Khayamzadeh M, Tadayon N, Salmanian R, Zham H, Razzaghi Z, et al. Survival of thyroid cancer and social determinants in Iran, 2001-2005. Asian Pac J Cancer Prev 2011; 12(1): 95-8.
Bastos HN, Antao MR, Silva SN, Azevedo AP, Manita I, Teixeira V, et al. Association of Polymorphisms in Genes of the Homologous Recombination DNA Repair Pathway and Thyroid Cancer Risk. Thyroid 2009; 19(10):1067-75.
Schlumberger M, Cailleux AF, Suarez HG, deVathaire F. Irradiation and second cancers: the thyroid as a case in point. C R AcadSci III 1999; 322(2-3): 205-13.
HorvaticHerceg G, Herceg D, Kralik M, Kulic A, Bence-Zigman Z, Tomic-Brzac H, et al. Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients. Otolaryngol Head Neck Surg 2013; 149(4): 533-40.
HorvaticHerceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomic-Brzac H, Kulic A. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien KlinWochenschr 2006; 118(19-20): 601-9.
Lei H, Hemminki K, Johansson R, Altieri A, Enquist K, Henriksson R, et al. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 2008; 109(1): 165-75.
YasarYildiz S, Kuru P, ToksoyOner E, Agirbasli M. Functional stability of plasminogen activator inhibitor-1. Scientific World Journal 2014; 858293.
Bonyadi M, Shaghaghi Z, Haghi M, Dastgiri S. Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis. Eur J Pediatr 2013; 172(1): 91-8.
Shaghaghi Z, Bonyadi M, Somi MH, Khoshbaten M. Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients. Saudi J Gastroenterol 2014; 20(1): 54-8.
Baldini E, Sorrenti S, DArmiento E, Di Matteo FM, Catania A, Ulisse S. The urokinase plasminogen activating system in thyroid cancer: clinical implications. G Chir 2012; 33(10): 305-10.
Wang S, Cao Q, Wang X, Li B, Tang M, Yuan W, et al. PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis. PloS One 2013; 8(2): 56797.
Younesi M, HosseinpourFeizi MA, Pouladi N. Evaluating the prevalence of plasminogen activator inhibitor-1 gene polymorphism in patients with thyroid tumors from North West of Iran. (Journal of Ilam University of medical sciences, in press) [Persian]
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3): 1215.
Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. ThrombHaemost 2005; 93(4): 631-40.
Blasiak J, Smolarz B. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. ActaBiochim Pol 2000; 47(1): 191-9.
Zhang X, Shu XO, Cai Q, Ruan Z, Gao YT, Zheng W. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res 2006; 12: 6037-42.
Castello R, Espana F, Vazquez C, Fuster C, Almenar SM, Aznar J, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006; 117(5): 487-92.
Sternlicht MD, Dunning AM, Moore DH, Pharoah PD, Ginzinger DG, Chin K, et al. Prognostic value of PAI 1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006; 15(11): 2107-14.
Lee JH, Kim Y, Choi JW, Kim YS. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Arch Med Res 2013; 44(1): 39-45.
Yagmurdur MC, Atac FB, Tutar NU, Verdi H, Isiklar I, Ozdemir BH, et al. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast. IntSurg 2008; 93(3): 163-8.
Younesi M, HosseinpourFeizi MA, Pouladi N. Clinicopathological significance of plasminogen activator inhibitor-1 gene polymorphism in breast cancer patients from North West of Iran. JSSU 2016:24(3): 277-85 [In Persian].